WarnkeCMengeTHartungHP. Natalizumab and progressive multifocal leukoencephalopathy: What are the causal factors? Can it be avoided?Arch Neurol2010; 67: 923–930.
2.
ShiraniAStüveO.Natalizumab for multiple sclerosis: A case in point for the impact of translational neuroimmunology. J Immunol2017; 198: 1381–1386.
3.
WarnkeCOlssonTHartungHP. The dark side of immunotherapy in multiple sclerosis. Trends Pharmacol Sci2015; 36: 799–801.
4.
BergerJRFoxRJ.Reassessing the risk of natalizumab-associated PML. J Neurovirol2016; 22: 533–535.
5.
WattjesMPWarnkeC.Guidelines on PML risk stratification and diagnosis in patients with MS treated with natalizumab: So far so good?J Neurol Neurosurg Psychiatry2015; 87: 115.
6.
SchmedtNAndersohnFGarbeE.Signals of progressive multifocal leukoencephalopathy for immunosuppressants: A disproportionality analysis of spontaneous reports within the US Adverse Event Reporting System (AERS). Pharmacoepidemiol Drug Saf2012; 21: 1216–1220.
7.
WinkelmannALoebermannMReisingerEC. Disease-modifying therapies and infectious risks in multiple sclerosis. Nat Rev Neurol2016; 12: 217–233.
8.
MolloyESCalabreseLH.Progressive multifocal leukoencephalopathy: A national estimate of frequency in systemic lupus erythematosus and other rheumatic diseases. Arthritis Rheum2009; 60: 3761–3765.
9.
MengeTDubeyDWarnkeC. Ocrelizumab for the treatment of relapsing-remitting multiple sclerosis. Expert Rev Neurother2016; 16: 1131–1139.
10.
KapposLLiDKBStüveO. Safety and efficacy of Siponimod (BAF312) in patients with relapsing-remitting multiple sclerosis: Dose-blinded, randomized extension of the phase 2 BOLD study. JAMA Neurol2016; 73: 1089–1098.
11.
FoleyJ.Natalizumab related PML: An evolving risk stratification paradigm. Neurology2013; 80(7): S30.002.
12.
Zhovtis RyersonLFrohmanTCFoleyJ. Extended interval dosing of natalizumab in multiple sclerosis. J Neurol Neurosurg Psychiatry2016; 87: 885–889.
13.
van KempenZLeursCVennegoorA. Natalizumab-associated progressive multifocal leukoencephalopathy is not preceded by elevated drug concentrations. Mult Scler2017; 23: 995–999.
